KRAS and cancer: Recognizing these challenges, we hypothesized that combining irinotecan‐loaded silicasomes, which locally induce ICD, with spleen‐targeting LNPs delivering KRAS mRNA may be able to synergistically activate the PDAC cancer immunity cycle (Figure 1).